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Four mexiletine analogues have been tested for their antiarrhythmic, inotropic, and chronotropic effects
on isolated guinea pig heart tissues and to assess calcium antagonist activity, in comparison with the
parent compound mexiletine. All analogues showed from moderate to high antiarrhythmic activity. In
particular, three of them (1b,c,e) were more active and potent than the reference drug, while exhibiting
only modest or no negative inotropic and chronotropic effects and vasorelaxant activity, thus showing
high selectivity of action. All compounds showed no cytotoxicity and 1b,c,d did not impair motor co-
ordination. All in, these new analogues exhibit an interesting cardiovascular profile and deserve further
investigation.
© 2016 Elsevier Masson SAS. All rights reserved.1. Introduction
One of the major causes of mortality is represented by cardio-
vascular diseases and about 25% of cardiovascular-related adverse
events are caused by arrhythmias. The term arrhythmia defines an
abnormality in the sequence and/or shape of electrical impulses
during the cardiac cycle. A critical role in the regulation of electrical
activity of cardiac cells is played by ion channels such as sodium,DMEM, Dulbecco’s modified
inal smooth muscle; HepG2,
Madin-Darby canine kidney;
,5-dimethylthiazol-2-yl)-2,5-
, P-glycoprotein; PSS, physio-
i).
served.calcium and potassium channels. Abnormalities in the expression
and/or function of ion channels are responsible of many arrhyth-
mias [1,2], thus, they represent one of the targets for antiarrhythmic
therapy. Indeed, most of the existing antiarrhythmic agents, such as
lidocaine, tocainide, and mexiletine [3,4] are ion channel blockers.
Mexiletine (1a, Fig. 1) is an antiarrhythmic drug belonging to class
IB. It is a voltage-gated sodium channel blocker whose mechanism
of action is related to its preferential binding to the open and/or
inactivated states of the channels. The selective action of mexiletine
on pathologically hyperactive tissues seems to be related to the
use-dependent blockade of sodium channels [5]. Mexiletine un-
dergoes extensive metabolism; eleven phase I metabolites of
mexiletine have been identified [6,7]. Mexiletine is predominantly
used in the treatment of ventricular arrhythmias, however, recent
studies have demonstrated its therapeutic value for treating many
other disorders associated with voltage-gated sodium channel
O
NH2
R
1a-e
a: R = Me
b: R = tBu
c: R = Ph
d: R = iPr
e: R = Bn
Fig. 1. Structures of mexiletine (1a) and its analogues (1bee).
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neuropathic pain [9], myotonic syndromes [10], and Timothy syn-
drome [11]. Recently, mexiletine has been successfully used in the
treatment of sporadic amyotrophic lateral sclerosis [12e14].
Despite all these reported therapeutic values, the use of mexiletine
is characterized by several drawbacks including epigastric
discomfort, atrioventricular heart block, and CNS disturbances [15].
Hence, it has now been discontinued in many countries including
the US and the UK [16]. Consequently, numerous attempts have
been made in recent years to develop an alternative to mexiletine,
including the design of new analogues that offer the same phar-
macological effect but without the unwanted side effects. In the
past decade, our own laboratories have been focusing on the
development of such analogues through which the structural de-
terminants for blocking voltage-gated sodium channels of skeletal
muscles have been established [17e20]. As these identified com-
pounds were more potent channel blockers than the parent com-
pound, they have been proposed as mexiletine alternatives for the
treatment of myotonias. We also established that the activity of
mexiletine-like sodium channel blockers is strongly linked to the
part of the molecule nearby the asymmetric carbon atom. In order
to evaluate the potential of these compounds for treating ar-
rhythmias, we selected the most interesting compounds from the
previously reported series (1cee, Fig. 1) that bear a bulky group at
the stereogenic center. These compounds, along with a new addi-
tional compound,1b, bearing a tert-butyl group as substituent were
prepared by alternative and efficient synthetic routes. The biolog-
ical activity of all compounds was assessed with due comparison
with mexiletine.2. Results and discussion
2.1. Chemistry
Mexiletine (1a) and its analogues (1b,c) were prepared in two
steps according to the synthetic route depicted in Scheme 1, carried
out in both traditional conditions and microwave-assisted syn-
thesis. In the first step, 2,6-dimethylphenol underwent Williamson
reaction [21] with the suitable halo ketone (2aec) to obtain ary-
loxyalkyl ketones (3aec) which were converted into the corre-
sponding amines 1aec by reductive amination under both
traditional and microwave conditions [22]. The corresponding hy-
drochloride salts (1aec·HCl) were obtained by treating 1aec with
gaseous HCl. Mexiletine analogues 1d,e were prepared as depicted
in Scheme 2. Compounds 5d,e were obtained by protecting the
corresponding commercial valinol and phenylalaninol,Scheme 1. Reagents and conditions: (i) 2,6-xylenol, K2CO3, anhyd DMF, rt, 24h (for 2a); 2,6
60 C, 15 min (for 2c); (ii) NaBH3CN, AcONH4, MeOH, rt (or MW, 110 C, 11 min); (iii) anhyrespectively, with di-tert-butyl dicarbonate [23,24]. Compounds
5d,e were subjected to Mitsunobu reaction with 2,6-
dimethylphenol as previously described [25]. The so obtained aryl
alkyl ethers 6d,e were treated with gaseous HCl to give the corre-
sponding amines as hydrochloride salts (1d,e·HCl).
2.2. Biological results
Mexiletine and its analogues (1aee) were tested in vitro for their
antiarrhythmic activity on guinea pig isolated left atria driven at
1 Hz. Compound 1b,c,e increased the threshold of ac-arrhythmia
more than mexiletine did, while 1d showed an anti-arrhythmic
activity comparable to that of the parent compound, mexiletine
(Table 1). In particular, compound 1cwas found to be 27-fold more
active than mexiletine. To better define the cardiac profile of
mexiletine analogues, their influence on additional cardiac pa-
rameters were compared with that elicited by the reference com-
pound, mexiletine (Table 2). All the tested compounds strongly
decreased the developed tension on driven left atria with EC50
values within the range of 0.012 and 0.042 mM. The most potent
analogue was 1e showing a negative inotropism 4-fold higher than
that of mexiletine (Table 2), while its antiarrhythmic potency was
2.7-fold higher than that of mexiletine (Table 1). The effect of 1b
was comparable to that of mexiletine. It is noteworthy that the
introduction of an aromatic moiety, in lieu of themethyl one, on the
stereogenic center as in 1c and 1e, strongly increased antiar-
rhythmic and negative inotropic potency. On the other hand, the
introduction of an isopropyl group, as in 1d, while slightly affecting
the antiarrhythmic activity, enhanced two times the negative
inotropic effect. With regard to the negative chronotropic activity
on spontaneously beating right atrium, only compound 1d showed
a weak activity, about 900-fold lower than that of mexiletine.
Furthermore, 1b,c,e showed negative inotropism on spontaneously
beating isolated right atrium, too. It is noteworthy that this effect
was not recorded for mexiletine and 1d due to their insignificant
inotropism resulting from chronotropic effect. Moreover, all the
new mexiletine analogues were tested on Kþ-depolarized (80 mM
KCl) guinea pig aortic strips to assess their vasorelaxant activity.
Data are shown in Table 3withmexiletine as the reference drug. For
all compounds, the intrinsic vasorelaxant activity percentage on
aorta was lower than 40% and thus unremarkable. In order to rule
out a possible inhibitory effect on nonvascular smoothmuscle, such
as that displayed by Ca2þ channel antagonists, further investigation
on relaxant activity using Kþ-depolarized (80 mM KCl) guinea pig
ileum longitudinal smooth muscle (GPILSM) was pursued (Table 3).
The observed profile of intrinsic activity and potency for 1b,c,dwas,
however, substantially similar to that displayed bymexiletine. Only
compound 1e showed a relaxant potency slightly higher than that
of the parent compound, but in the micromolar range. Over all, all
the compounds appears to display a higher intrinsic activity in
nonvascular than vascular smooth muscle cells. Since mexiletine
clinical use is often associated to CNS toxicity, a preliminary toxi-
cological evaluation of mexiletine analogues was performed by
assessing the motor coordination of treated animals using the rota-
rod test (Table 4). All compounds at the dose of 25 mg/kg ip did not-xylenol, K2CO3, MeOH, MW, 100 C, 20 min (for 2b); 2,6-xylenol, NaOH, DMSO, MW,
d Et2O, gaseous HCl.
Scheme 2. Reagents and conditions: (i) Boc2O, 1 M NaOH, THF, rt; (ii) 2,6-xylenol, DIAD, PPh3, anhyd THF, rt; (iii) anhyd Et2O, gaseous HCl.
Table 1
Antiarrhythmic activity of compounds 1aee.
Compd Max % increasea (mean ± SEM) EC50b (mM) 95% confidence limit (106)
1a 64 ± 1.4 11.6 8.71e13.5
1b 71 ± 2.4c 2.11 1.38e3.20
1c 135 ± 2.2d 0.43 0.34e0.54
1d 145 ± 4 18.4 14.9e22.7
1e 169 ± 4c 4.36 1.47e6.38
a Increase of threshold of ac-arrhythmia: increase in the intensity of 50 Hz alternating current required to produce arrhythmia in guinea pig left atria driven at 1 Hz in
the presence of each tested compounds at 104 M. For all data P < 0.05.
b Calculated from log concentration-response curves (Probit analysis according to Litchfield and Wilcoxon [35] with n ¼ 6e8). When the maximum effect was <50%,
the EC50 values were not calculated.
c At 105 M.
d At 5  106 M.
Table 2
Influences of tested compounds on cardiovascular parameters.
Compd Left atrium Right atrium
Negative inotropy Negative inotropy Negative chronotropy
Activitya
(% ± SEM)
EC50b
(mM)
95% confidence lim
(106)
Activityc
(% ± SEM)
EC50b
(mM)
95% confidence lim
(106)
Activityd
(% ± SEM)
EC50b
(mM)
95% confidence lim
(106)
1a 90 ± 1* 0.045 0.035e0.058 85 ± 3*g 0.014 0.009e0.023
1b 92 ± 1* 0.042 0.027e0.060 77 ± 1 1.02 0.85e3.05 7.0 ± 0.3i
1c 94 ± 2*e 0.029 0.017e0.052 54 ± 2h 8.2 4.6e10.4 11 ± 1i
1d 84 ± 2*f 0.021 0.012e0.037 55 ± 2*f 13.1 10.1e15.0
1e 79 ± 2*g 0.012 0.010e0.015 57 ± 3 0.066 0.048e0.091 24 ± 2*
a Decrease in developed tension on isolated guinea-pig left atrium at 105 M, expressed as percentage change from the control (n ¼ 5e6). The left atria were driven at 1 Hz.
The 105 M concentration gave the maximum effect for most compounds.
b Calculated from log concentration-response curves (Probit analysis by Litchfield and Wilcoxon [35] with n ¼ 6e7). When the maximum effect was <50%, the EC50
inotropic, EC50 chronotropic and IC50 vasorelaxant values were not calculated.
c Decrease in developed tension on guinea-pig spontaneously beating isolated right atrium at 5  106 M, expressed as percent changes from the control (n ¼ 7e8). The
5  106 M concentration gave the maximum effect for most compounds.
d Decrease in atrial rate on guinea-pig spontaneously beating isolated right atria at 105 M, expressed as the percentage change from the control (n ¼ 7e8). The 105 M
concentration gave the maximum effect for most compounds. The pretreatment heart rate ranged from 170 to 195 beats/min.
e At 5  106 M.
f At 104 M.
g At 107 M.
h At 105 M.
i P > 0.05. An asterisk indicates P < 0.05.
Table 3
Relaxant activity of compounds on Kþ-depolarized guinea pig vascular and non-vascular smooth muscle.
Compd Aorta Ileum
Activitya (% ± S.E.M.) Activitya (% ± S.E.M.) IC50b (mM) 95% confidence lim (106)
1a 5.0 ± 0.3 81 ± 2 8.5 6.5e11.1
1b 38 ± 2 73 ± 2c 10.7 9.0e12.8
1c 31 ± 2 75 ± 3d 13.8 10.8e17.5
1d 11 ± 1 88 ± 1 19.6 12.0e25.0
1e 33 ± 1 73 ± 2d 3.6 2.8e4.6
a Percent inhibition of calcium-induced contraction on Kþ-depolarized (80 mM) guinea pig aortic strips and longitudinal smooth muscle at 104 M. The 104 M concen-
tration gave the maximum effect for most compounds.
b Calculated from log concentration-response curves (Probit analysis by Litchfield and Wilcoxon [35] with n ¼ 6e7). When the maximum effect was <50%, the IC50 values
were not calculated.
c At 5  105 M.
d At 105 M.
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Table 4
Effect of mexiletine and its analogues on motor coordination expressed as number of falls from Rota-rod.a
Treatment Dose, mg kg1 ip Falls from the rota-rod
Before treatment After treatment
30 min 45 min 60 min
Saline 4.4 ± 1.1 2.5 ± 0.7 1.2 ± 0.5 0.9 ± 0.3
1ab 25 2.8 ± 0.5 1.3 ± 0.4 0.8 ± 0.3 e
1ab 50 2.4 ± 0.3 3.8 ± 0.3 3.5 ± 0.2 e
1b 25 4.6 ± 0.5 2.7 ± 0.4 1.7 ± 0.4 0.8 ± 0.2
1b 50 4.7 ± 0.4 3.1 ± 0.3 1.8 ± 0.5 1.2 ± 0.6
1c 25 4.3 ± 0.5 2.4 ± 0.3 1.8 ± 0.4 1.3 ± 0.3
1c 50 4.5 ± 0.6 3.2 ± 1.6 2.8 ± 0.7 1.0 ± 0.2
1d 25 4.8 ± 0.7 2.6 ± 0.8 2.2 ± 0.6 1.1 ± 0.3
1d 50 4.5 ± 0.6 3.0 ± 1.4 2.1 ± 1.3 1.0 ± 1.2
1e 25 4.5 ± 0.9 2.9 ± 0.8 1.9 ± 0.5 1.2 ± 0.5
1e 50 4.2 ± 0.8 4.4 ± 1.1* 3.5 ± 0.9* 1.3 ± 1.1
*P < 0.05 in comparison with saline-treated mice.
a Each value represents the mean of 8 mice.
b Ref. [16].
M. Roselli et al. / European Journal of Medicinal Chemistry 121 (2016) 300e307 303provoke any change in normal behavior of mice as demonstrated in
rota-rod experiments. At the dose of 50 mg/kg ip, only compound
1e showed a significant impairment of mouse motor coordination,
with a slight increase in the number of falls being displayed. Since
mexiletine is known to undergo extensive first-pass oxidative
metabolism [16,26,27] that is linked to the generation of reactive
species metabolites and/or cellular oxidative stress, the cytotoxicity
of the four analogueswas assessed using theMTTcell viability assay
[28].When the human hepatocellular liver carcinoma cells (HepG2)
were challenged with the four mexiletine analogues at two con-
centrations (the first close to their corresponding EC50 values, and
the second 10-fold higher than the former), no cytotoxicity was
observed (data not shown). This finding was in agreement with the
previous report for mexiletine where cell viability was not affected
at similar concentration range [16]. In addition, we tried to verify if
these analogues may display differential ability to interact with P-
glycoprotein (P-gp), an ATPase protein highly expressed in biolog-
ical membranes, that generally affects pharmacokinetics, efficacy,
safety, and tissue levels of drugs. For this, drug-protein interaction
was assessed for each compound by using the Madin-Darby canine
kidney (MDCK) cells overexpressing the ATPase protein P-gp
(MDCK-MDR1). As shown in Table 5, only compounds that bear a
phenyl ring near the basic center (1c,e) was able to bind P-gp. This
data was in good agreement with a recent study on a series of
structurally related rigid analogues [29].
3. Conclusions
Four mexiletine analogues differing for the substituent on the
stereogenic center have been tested for their antiarrhythmic,
inotropic, and chronotropic effects on isolated guinea pig heart
tissues and for their calcium antagonist activity on GPILSM, inTable 5
P-gp interaction of mexiletine (1a) and its analogues (1bee).
Compd EC50 ± SEM,a mM P-gp
1a NAb,c
1b NAb
1c 27 ± 5
1d NAb
1e 8.4 ± 1.5
a The value is the mean of three different experiments,
samples in duplicate.
b NA ¼ No activity at 100 mM.
c Ref. [31].comparison with mexiletine. Even if with different degrees of po-
tency, antiarrhythmic activity has been observed in all the studied
compounds, conceivably suggesting the hypothesis that the sub-
stitution of the methyl group of mexiletine with a bulky one,
strengthens the interaction with the biological structures involved
in the regulation of heart activity. In particular, compounds 1b,c,e
showed high antiarrhythmic activity, exhibiting EC50 values in the
range between 0.43 and 4.36 mM, thus comparing favorably with
the reference drug mexiletine (EC50 ¼ 11.6 mM). These compounds
exhibit an interesting cardiovascular profile, being endowed with
high antiarrhythmic activity and potency with only modest or no
negative inotropic and chronotropic effects and vasorelaxant ac-
tivity. When administered intraperitoneally (25 mg kg1), all
compounds did not impair motor coordination as demonstrated in
rota-rod experiments and showed no in vitro cytotoxicity at con-
centration 10 times higher than the corresponding antiarrhythmic
EC50 values. On the basis that the observed favorable profile should
not be affected by interaction with P-gp, compounds 1b and 1d
could be considered as the preferred choices. Taken all the data
together, this work afforded compounds endowed with better
antiarrhythmic activity along with similar or less cardiovascular
effects than mexiletine, thus presenting a higher selectivity of ac-
tion and reduced side effects. In this respect, the t-butyl substituted
mexiletine analogue 1b seems to be the most interesting com-
pound. Further investigation would allow more complete knowl-
edge about its pharmacological potential and mechanism of action,
which in turn might allow the design and development of even
more active and potent antiarrhythmic agents.4. Experimental protocols
4.1. Chemistry
Chemicals were purchased from Sigma-Aldrich or Lancaster.
Yields refer to purified products and were not optimized. The
structures of the compounds were confirmed by routine spectro-
metric and spectroscopic analyses. Only spectra for compounds not
previously described are given. The reaction under microwaves
irradiation were carried out at constant temperature in a CEM
Discover BenchMate microwave reactor, with continuous stirring.
The temperature was measured and controlled by a built-in
infrared detector. Melting points were determined on a Gallen-
kamp apparatus in open glass capillary tubes and are uncorrected.
Infrared spectra were recorded on a Perkin-Elmer (Norwalk, CT)
Spectrum One FT spectrophotometer and band positions are given
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were recorded on either a Varian VX Mercury spectrometer oper-
ating at 300 and 75MHz for 1H and 13C, respectively, or an AGILENT
500MHz operating at 500 and 125MHz for 1H and 13C, respectively,
using CDCl3 and CD3OD as solvents. Chemical shifts (d) are reported
in ppm relative to the residual non-deuterated solvent resonance:
CDCl3, d ¼ 7.26 (1H NMR) and d ¼ 77.3 (13C NMR); CD3OD, d ¼ 3.30
(1H NMR) and d ¼ 47.8 (13C NMR) as internal references. Coupling
constants (J) are given in Hz. Gas chromatography (GC)/mass
spectroscopy (MS) was performed on a Hewlett-Packard
6890e5973 MSD at low resolution. Liquid chromatography (LC)/
mass spectroscopy (MS) was performed on a spectrometer Agilent
1100 series LC-MSD Trap System VL. Elemental analyses were
performed on a Eurovector Euro EA 3000 analyzer and the data for
C, H, N were within ±0.4 of theoretical values. Chromatographic
separations were performed on silica gel columns by column
chromatography on silica gel (Kieselgel 60, 0.040e0.063 mm,
Merck, Darmstadt, Germany) as described by Still et al. [30]. TLC
analyses were performed on precoated silica gel on aluminum
sheets (Kieselgel 60 F254, Merck).
4.1.1. 1-(2,6-Dimethylphenoxy)propan-2-amine (1a)
The preparation of 1a was performed under both traditional
(method A) and microwaves conditions (method B) [31].
4.1.1.1. Method A. Ammonium acetate (23.8 g, 310 mmol) and so-
dium cyanoborohydride (1.4 g, 21.7 mmol) were added to a solution
of 1-(2,6-dimethylphenoxy)propan-2-one (3a) (5.5 g, 31 mmol) in
40 mL of MeOH. The reaction mixture was stirred for four days at
room temperature. 6 M HCl was added dropwise to the mixture
reaction to destroy the excess hydride. The organic solvent was
removed under vacuum and the residue aqueous phase was made
alkaline with NaOH pellets. Then, the aqueous phase was extracted
with AcOEt and the combined organic phases were dried (Na2SO4).
The solvent was evaporated under reduced pressure to give the
desired amine (1a) as a yellow oil (4.5 g, 81%). Spectroscopic data
were in agreement with the literature [21].
4.1.1.2. Method B. In a microwave tube, ammonium acetate (7.35 g,
95.5 mmol) and sodium cyanoborohydride (0.42 g, 6.7 mmol) were
added to a solution of 1-(2,6-dimethylphenoxy)propan-2-one (3a)
(1.7 g, 9.55 mmol) in 15 mL of MeOH. The reaction mixture was
stirred for 11min at 110 C in a microwave reactor at 95Was power
max. The processing of reaction mixture was carried out as re-
ported for method A, obtaining 1a in 72% yield. Spectrometric and
spectroscopic data were in agreement with the literature [21].
4.1.2. 1-(2,6-Dimethylphenoxy)propan-2-amine hydrochloride
(1a·HCl)
1a was treated with gaseous HCl to obtain the corresponding
hydrochloride salt (1a·HCl) as a white solid which was recrystal-
lized from EtOH/Et2O to afford 2.9 g (40%) of white crystals: mp
215e216 C; 1H NMR (500MHz, DMSO-d6): d 1.35 (d, J¼ 6.8 Hz, 2H,
CH3CH), 2.23 (s, 6H, CH3Ar), 3.50e3.58 (m, 1H, CH), 3.82 (d,
J¼ 5.4 Hz, 2H, CH2), 6.91 (t, J¼ 6.8 Hz, 1H, Ar), 6.93 (t, J¼ 7.3 Hz, 1H,
Ar), 7.00 (d, J ¼ 7.8 Hz, 2H, Ar), 8.50 (br s, 3H, NH3þ); 13C NMR
(125 MHz, DMSO-d6): d 15.5 (2C), 16.4 (1C), 47.3 (1C), 72.2 (1C),
124.7 (1C), 128.9 (2C), 129.3 (2C), 130.9 (2); 154.8 (1C); Anal.
(C11H18NOCl) C, H, N.
4.1.3. 1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-amine (1b)
Prepared as reported for 1a (Method B) starting from 3b. The
synthetic pathway provided 1b as a yellow oil in 34% yield. 1H NMR
(500 MHz, CDCl3): d 0.97 (s, 9H, (CH3)3C), 1.99 (br s, 2H, NH2), 2.30
(s, 6H, CH3Ar), 3.02 (dd, J ¼ 9.3, 2.9 Hz, 1H, CHH), 3.63 (t, J ¼ 9.3 Hz,1H, CH), 3.84 (dd, J¼ 9.3, 2.9 Hz,1H, CHH), 6.93 (t, J¼ 7.3 Hz, 1H, Ar)
7.02 (d, J ¼ 7.3 Hz, 2H, Ar); 13C NMR (125 MHz, CDCl3): d 15.3 (1C),
16.4 (1C), 26.5 (3C), 33.0 (1C), 60.5 (1C), 65.9 (1C), 123.9 (1C), 128.9
(2C), 130.9 (2C), 155.8 (1C); GC-MS (70 eV) m/z (%) 221 (Mþ, 1), 86
(100).
4.1.4. 1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-amine
hydrochloride (1b·HCl)
Obtained as reported above for 1a$HCl: yield: 71%; white crys-
tals; mp: 215e216 C (abs EtOH/Et2O). Anal. (C14H24NOCl) C, H, N.
4.1.5. 2-(2,6-Dimethylphenoxy)-1-phenylethanamine (1c)
Prepared as reported for 1a (Method B) starting from 3c. The
synthetic pathway provided 1c as a yellow oil in 26% yield. 1H NMR
(500 MHz, CDCl3): d 2.17 (s, 6H, CH3Ar), 3.88e4.08 (m, 2H, CH2),
4.50e4.57 (m,1H, CH), 6.88e7.03 (m, 3H, Ar), 7.13e7.22 (m, 3H, Ar),
7.24e7.38 (m, 2H, Ar), 7.50 (d, J ¼ 6.8 Hz, 2H, CH2); 13C NMR
(125 MHz, CDCl3): d 15.3 (1C), 16.3 (1C), 21.5 (1C), 65.9 (1C), 124.2
(1C), 125.3 (1C), 126.8 (1C), 127.4 (1C), 128.2 (1C), 128.6 (1C), 128.7
(1C), 128.9 (1C), 129.0 (2C), 130.8 (1C), 137.9 (1C); GC-MS (70 eV)m/
z (%) 241 (Mþ, <1), 106 (100).
4.1.6. 2-(2,6-dimethylphenoxy)-1-phenylethanamine hydrochloride
(1c·HCl)
Obtained as reported above for 1a.HCl: yield: 80%; white crys-
tals; mp: 259e261 C (abs EtOH/Et2O); Anal. (C16H20NOCl) C, H, N.
4.1.7. 1-(2,6-Dimethylphenoxy)-3-methylbutan-2-amine
hydrochloride (1d·HCl)
A solution of 5d (2.5 g, 8.1 mmol) in anhydrous Et2O (15mL) was
saturated with gaseous HCl and stirred at room temperature for
15 min. Removal of the solvent under reduced pressure gave a solid
(1.5 g, 75%) which was recrystallized from EtOH/Et2O: white crys-
tals: mp 171e172 C (abs EtOH/Et2O); Anal. (C13H22NOCl.0.17H2O)
C, H, N.
4.1.8. 1-(2,6-Dimethylphenoxy)-3-methylbutan-2-amine (1d)
Obtained as a yellow oil by extraction from the corresponding
hydrochloride salt. 1H NMR (500 MHz, CDCl3): d 0.98 (d, J ¼ 7.3 Hz,
3H, CH3CHCH3), 0.99 (d, J ¼ 6.8 Hz, 3H, CH3CHCH3), 1.73e1.82 (m,
1H, CHCH3), 1.88 (br s, 2H, NH2), 2.30 (s, 6H, CH3Ar), 2.98e3.08 (m,
1H, CHCH2), 3.64 (t, J¼ 8.8 Hz,1H, CHHCH2), 3.77 (dd, J¼ 3.8, 8.8 Hz,
1H, CHHCH2), 6.92 (t, J ¼ 7.8 Hz, 1H, Ar), 7.01 (d, J ¼ 7.8 Hz, 2H, Ar);
13C (125 MHz, CDCl3): d 15.3 (1C), 16.4 (1C), 18.2 (1C), 19.4 (1C), 30.8
(1C), 57.1 (1C), 65.9 (1C), 123.8 (1C), 128.9 (2C). 129.0 (1C), 130.1
(1C), 155.7 (1C); MS (70 eV) m/z (%) 207 (Mþ, 3), 72 (100).
4.1.9. 1-(2,6-Dimethylphenoxy)-3-phenylpropan-2-amine
hydrochloride (1e·HCl)
Prepared as reported for 1d$HCl starting from 5e. The synthetic
pathway provided 1e$HCl as a white solid in 92% yield. The solid
was recrystallized from abs EtOH/Et2O to give white crystals (40%);
mp: 218e219 C. 1H NMR (300 MHz, CD3OD): d 2.21 (s, 6H, CH3Ar),
3.02e3.24 (m, 2H, CH2Ar), 3.72e4.0 (m, 3H, CH2CH), 6.95e7.05 (m,
3H, Ar), 7.25e7.45 (m, 5H, Ar); 13C NMR (100 MHz, CD3OD): d 15.3
(2C), 35.4 (1C), 53.5 (1C), 70.0 (1C), 124.6 (1C),127.4 (1C),129.0 (4C),
129.1 (2C), 130.5 (2C). 135.5 (1C), 154.6 (1C). Anal. (C17H22NOCl) C,
H, N.
4.2. Pharmacology
4.2.1. Details for functional studies
4.2.1.1. Guinea-pig atrial preparations. Female guinea pigs
(300e400 g) were sacrificed by cervical dislocation. After thora-
cotomy, the heart was immediately removed and washed by
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following composition (mM): 136.9 NaCl, 5.4 KCl, 2.5 CaCl2, 1.0
MgCl2, 0.4 NaH2PO4xH2O, 11.9 NaHCO3 and 5.5 glucose. The phys-
iological salt solution (PSS) was buffered at pH 7.4 by saturation
with 95% O2e5% CO2 gas, and the temperature was maintained at
35 C. Isolated guinea pig heart preparations were used, sponta-
neously beating right atria and left atria driven at 1 Hz. For each
preparation, the entire left and right atria were dissected from the
ventricles, cleaned of excess tissue, and hung vertically in a 15 mL
organ bath containing the PSS continuously bubbled with 95%
O2e5% CO2 gas at 35 C, pH 7.4. The contractile activity was
recorded isometrically bymeans of a force transducer (FT 0.3, Grass
Instruments Corporation, Quincy, MA, USA) using Power Lab®
software (AD-Instruments Pty Ltd, Castle Hill, Australia). The left
atria were stimulated by rectangular pulses of 0.6e0.8 ms duration
and about 50% threshold voltage through two platinum contact
electrodes in the lower holding clamp (Grass S88 Stimulator). The
right atrium was in spontaneous activity. After the tissue was
beating for several minutes, a length-tension curve was deter-
mined, and themuscle lengthwasmaintainedwhich elicited 90% of
maximum contractile force observed at the optimal length. A sta-
bilization period of 45e60 min was allowed before the atria were
used to test compounds. During the equilibration period, the
bathing solution was changed every 15 min and the threshold
voltagewas ascertained for the left atria. Atrial muscle preparations
were used to examine the inotropic and chronotropic activity of the
compounds (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 mM) dissolved in
PSS. During the construction of cumulative dose-response curves,
the next higher concentration of the compounds was added only
after the preparation reached a steady state.
4.2.1.2. Alternating current induced arrhythmia in Guinea pig left
atrial preparations [32,33]. Left atria from guinea pigs were fixed to
platinum wire electrodes and placed between two parallel plat-
inum field electrodes. The preparations were mounted vertically in
a 15 mL organ bath containing a modified Krebs-Henselait solution
of the following composition (mM): 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2
MgSO4, 1.2 NaH2PO4xH2O, 24.9 NaHCO3, and 10.1 glucose. The so-
lutionwas buffered at pH 7.4 by saturationwith 95% O2e5% CO2 gas,
and the temperature was maintained at 35 C. The preparations
were connected to a force transducer. Isometric force contraction
was recorded using Power Lab® software. Arrhythmias were
induced by application of sinusoidal alternating current (50 Hz) of
increasing strength to the isolated heart preparations, 2 and 4 mA/
(cm2 s) to induce arrhythmia corresponding to an increase in field
intensity of 0.3 V/(cm s). The current intensity (mA/cm2) at which
extra beats occurred was called “threshold of ac-arrhythmia” [34].
The preparations were allowed to stabilize for 60 min. Then
concentration-response curves for threshold of ac-arrhythmiawere
recorded by cumulative application of compounds to the bathing
solution every 30 min.
4.2.1.3. Guinea-Pig aortic strips. The thoracic aorta was removed
and placed in Tyrode solution of the following composition (mM):
118 NaCl, 4.75 KCl, 2.54 CaCl2, 1.20 MgSO4, 1.19 KH2PO4, 25 NaHCO3
and 11 glucose equilibrated with 95% O2e5% CO2 gas at pH 7.4. The
vessel was cleaned of extraneous connective tissue. Two helicoidal
strips (10 mm  1 mm) were cut from each aorta beginning from
the end most proximal to the heart. Vascular strips were then tied
with surgical thread (6-0) and suspended in a jacketed tissue bath
(15 mL) containing aerated PSS at 35 C. Aortic strips were sub-
jected to a resting force of 1 g. Strips were secured at one end to a
force displacement transducer (FT 0.3, Grass Instruments Corpo-
ration) to monitor changes in isometric contraction and washed
every 20 min with fresh PSS for 1 h after the equilibration period;guinea pig aortic strips were contracted by washing in PSS con-
taining 80 mM KCl (equimolar substitution of Kþ for Naþ). After the
contraction reached a plateau (about 45 min) the compounds (0.1,
0.5, 1, 5, 10, 50, and 100 mM) were added cumulatively to the bath
allowing for any relaxation to obtain an equilibrated level of force.
Addition of the drug vehicle had no appreciable effect on Kþ-
induced contraction (PSS for all compounds).
4.2.1.4. Statistical analysis. Data were analyzed using Student’s t-
test and are presented asmean ± S.E.M. Since the drugs were added
in cumulative manner, the difference between the control and the
experimental values at each concentration were tested for a P
value < 0.05. The potency of drugs defined as EC50 and IC50 was
evaluated from log concentration-response curves (Probit analysis
using Litchfield and Wilcoxon) [35] in the appropriate pharmaco-
logical preparations.
4.2.2. Details for motor coordination studies
4.2.2.1. Rota-rod test. The apparatus consisted of a base platform
and a rotating rod of 3 cm diameter with a non-slippery surface.
The rod was placed at a height of 15 cm from the base. The rod,
30 cm in length, was divided into five equal sections by six disks.
Thus, up to five mice were tested simultaneously on the apparatus,
with a rod-rotating speed of 16 rpm. The integrity of motor coor-
dination was assessed on the basis of the number of falls from the
rod in 30 s according to Vaught et al. [36].
4.2.3. Details for cytotoxicity studies
4.2.3.1. Cell cultures. HepG2 (Sigma-Aldrich, St. Louis, MO) cells
were cultured in DMEM-Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% (v/v) inac-
tivated fetal bovine serum (PAA Laboratories GmbH, Austria), 2 mM
L-glutamine (Sigma-Aldrich, St. Louis, MO), 100 mg/mL penicillin
and 100 mg/mL streptomycin (Sigma-Aldrich, St. Louis, MO) at 37 C
in 5% CO2. For experiments, the cells were grown to 70% confluence
and thenwere treatedwith test compounds in serum freemedia for
the indicated times.
4.2.3.2. Cell viability assay. HepG2 cell viability was assessed using
a conventional MTT reduction assay [37]. This method is based on
the ability of viable cells to metabolize MTT, a water-soluble salt
(yellow color), by cellular oxidoreductase into a water-insoluble
blue formazan product. Therefore, the amount of formazan pro-
duced is proportional to the viable cells. Briefly, viable cells (104/
well) were plated into sterile 96-Well Cell Culture Cluster (Corning,
NY 14831) and incubated with different concentrations
(0.05e2 mM) of tested compounds for 2 h at 37 C in 5% CO2. At the
end of incubation, the culturemediumwas replaced by a solution of
MTT 0.5 mg/mL (Sigma-Aldrich, Milan, Italy) in PBS (Sigma-Aldrich,
Milan, Italy). After 2 h incubation at 37 C in 5% CO2 this solution
was removed and 200 ml of DMSO was added to each well to
dissolve the formazan product. Absorbance values at 570 nm were
measured using a plate reader Victor V3 (Perkin-Elmer) and DMSO
medium was used as blank solution. Results are expressed as the
percentage of MTT reduction respect to control cells. All experi-
ments were carried out in sextuplicate and were repeated twice.
4.2.4. Details for P-gp interaction studies
4.2.4.1. Cell cultures. MDCK-MDR1 cells are a gift of Prof. P. Borst,
NKI-AVL Institute, Amsterdam, Netherland. MDCK cells were grown
in DMEM high glucose supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, in a
humidified incubator at 37 C with a 5% CO2 atmosphere.
4.2.4.2. Calcein-AM experiment. These experiments were carried
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cell line (50,000 cells per well) was seeded into black CulturePlate
96/wells plate with 100 ml medium and allowed to become
confluent overnight. 100 ml of test compounds were solubilized in
culture medium and added to monolayers. 96/Wells plate was
incubated at 37 C for 30 min. Calcein-AM was added in 100 ml of
Phosphate Buffered Saline (PBS) to yield a final concentration of
2.5 mMand platewas incubated for 30min. Each well was washed 3
times with ice cold PBS. Saline buffer was added to each well and
the plate was read to Victor3 (PerkinElmer) at excitation and
emissionwavelengths of 485 nm and 535 nm, respectively. In these
experimental conditions Calcein cell accumulation in the absence
and in the presence of tested compounds was evaluated and fluo-
rescence basal level was estimated by untreated cells. In treated
wells the increase of fluorescence with respect to basal level was
measured. EC50 values were determined by fitting the fluorescence
increase percentage versus log [dose].
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